{"product_id":"fruzaqla-fruquintinib","title":"Fruzaqla  (Fruquintinib)","description":"\u003ch2\u003eAbout Fruquintinib\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eFruquintinib (Fruzaqla) \u003c\/strong\u003e sold under the brand name 爱优特 in china, is an oral, highly selective, small molecule VEGF receptor inhibitor. Because of the kinase selectivity of Fruzaqla, the risk of off-target toxicity is less than the risk with multikinase inhibitors, including regorafenib.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFruquintinib продается под торговой маркой Fruzaqla в США\u003c\/li\u003e\n\u003cli\u003eFruquintinib продается под торговой маркой ELUNATE в Гонконге\u003c\/li\u003e\n\u003cli\u003eFruquintinib продается под торговой маркой 爱优特 в Китае\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003eApproval\u003c\/h2\u003e\u003ch3\u003eNovember 9, 2023\u003c\/h3\u003e\u003cp\u003eThe FDA has approved fruquintinib (Fruzaqla) to treat adults with metastatic colorectal cancer who received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy for cases that are \u003cem\u003eRAS\u003c\/em\u003e wild-type and medically appropriate.\u003c\/p\u003e\u003ch3\u003eJune 21, 2024\u003c\/h3\u003e\u003cp\u003eThe European Commission (“EC”) that it has approved FRUZAQLA\u003csup\u003e®\u003c\/sup\u003e (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (“CRC”) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.\u003c\/p\u003e\u003ch3\u003eSeptember 24, 2024\u003c\/h3\u003e\u003cp\u003eThe Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg\/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy.\u003c\/p\u003e","brand":"HUTCHMED Biopharmaceutical Company，china","offers":[{"title":"Default Title","offer_id":44797952196651,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2243.jpg?v=1787022169","url":"https:\/\/xomeds.com\/products\/fruzaqla-fruquintinib","provider":"XOMEDS","version":"1.0","type":"link"}